Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 DDI and Gastric Emptying Study in Obese Subjects
NCT07128888Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of bofanglutide in obesity, sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum plasma concentration at 16 weeks, Area under the plasma concentration-time curve at 0 h to last observation time-point and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
bofanglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07128888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128888.